Locations
Conditions
Treatments
Institutions
Resources
For researchers
About us
Clinical trials
A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
Apply
Rilvegostomig vs. Pembrolizumab
A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
Basic information
Step 1/5
Provide your basic information
Age
ZIP code
Back
Next step